Cargando…
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multip...
Autores principales: | Terao, Toshiki, Yamashita, Takeshi, Fukumoto, Ami, Kamura, Yuya, Ikeda, Daisuke, Kuzume, Ayumi, Tabata, Rikako, Tsushima, Takafumi, Miura, Daisuke, Narita, Kentaro, Takeuchi, Masami, Doi, Masahiro, Umezawa, Yuka, Otsuka, Yoshihito, Takamatsu, Hiroyuki, Matsue, Kosei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860256/ https://www.ncbi.nlm.nih.gov/pubmed/35190963 http://dx.doi.org/10.1007/s12185-022-03300-4 |
Ejemplares similares
-
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
por: Tsushima, Takafumi, et al.
Publicado: (2022) -
Antibody response to COVID-19 vaccination in patients with lymphoma
por: Narita, Kentaro, et al.
Publicado: (2022) -
Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
por: Ikeda, Daisuke, et al.
Publicado: (2022) -
Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib
por: Ikeda, Daisuke, et al.
Publicado: (2022) -
Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
por: Narita, Kentaro, et al.
Publicado: (2021)